Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
4
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
4
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
indiana blog main
indiana top stories
cancer
ceo
clinical trials
commissioner
gene editing
ipo
lung cancer
merck
roche
scott gottlieb
shutdown
abbvie
What
medicine
4
×
bio
cancer
drug
fda
roundup
approved
big
biopharma
bosley's
bosley’s
bridge
bucks
car
cas
celgene
ceo
colleagues
crime
crispr
deeper
departure
dna
editas
eisai
exit
exome
fingerprint
flags
genetic
going
government
guiding
health
higher
hundreds
incidence
industry
katrine
lorcaserin
Language
unset
Current search:
fda
×
medicine
×
" seattle blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues